Additional file 1 of A time trade-off study to determine health-state utilities of transplant recipients with refractory cytomegalovirus infection with or without resistance

Additional file1. Table S1. Summary of participants' clinical experience. Table S2. Final vignette: Clinically significant and symptomatic CMV (CS-symptomatic CMV). Table S3. Final vignette: Clinically significant and symptomatic CMV (CS-symptomatic CMV) with GvHD. Table S4. Final vignette: Clinically significant and symptomatic CMV (CS-symptomatic CMV) with kidney graft loss. Table S5. Final vignette: Clinically significant and symptomatic CMV (CS-symptomatic CMV) with lung graft loss. Table S6. Final vignette: Clinically significant and asymptomatic CMV (CS-asymptomatic CMV). Table S7. Final vignette: Clinically significant and asymptomatic CMV (CS-asymptomatic CMV) with GvHD. Table S8. Final vignette: Clinically significant and asymptomatic CMV (CS-asymptomatic CMV) with kidney graft loss. Table S9. Final vignette: Clinically significant and asymptomatic CMV (CS-asymptomatic CMV) with lung graft loss. Table S10. Final vignette: Non-clinically significant CMV (non-CS CMV). Table S11. Final vignette: Non-clinically significant CMV (non-CS CMV) with GvHD. Table S12. Final vignette: Non-clinically significant CMV (non-CS CMV) with kidney graft loss. Table S13. Final vignette: Non-clinically significant CMV (non-CS CMV) with lung graft loss